FID-007 and Cetuximab in Treating Patients With Advanced Head and Neck Squamous Cell Carcinoma

Recruiting

Phase 2

FID-007 and Cetuximab in Treating Patients With Advanced Head and Neck Squamous Cell CarcinomaFID-007 and Cetuximab in Treating Patients With Advanced Head and Neck Squamous Cell Carcinoma

Sponsor:

Fulgent Pharma LLC.

Code:

NCT06332092

Conditions

Head and Neck Squamous Cell Carcinoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

FID007

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-03-28. This information was provided to ClinicalTrials.gov by Fulgent Pharma LLC. on 2024-11-07.